GlaxoSmithKline PLC — Regulatory Filings 2012

Apr 16, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For period ending April 2012

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

The Administrators of the Deferred Investment Award Programme notified the Company and the under-mentioned persons on 16 April 2012 of an increase in their notional interests in Ordinary Shares at a price of 1407.25 pence per Share following the re-investment of the dividend paid to shareholders on 12 April 2012.

Mr E J Gray	127.957
Mr S A Hussain	893.492
Mr D S Redfern	199.727
Ms C Thomas	124.829
Dr P J T Vallance Ms E Walmsley Mr C Weber	96.566 930.117 127.957
Mrs V A Whyte	246.690

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

16 April 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: April 16, 2012

By: VICTORIA WHYTE

---

Victoria Whyte

Authorised Signatory for and on

behalf of GlaxoSmithKline plc